Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cord blood-derived expanded allogeneic natural killer cells
- Development stage
- Phase 2
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Cord blood-derived expanded allogeneic natural killer (NK) cells are a cell therapy product consisting of NK cells isolated from human umbilical cord blood and subsequently expanded ex vivo. These allogeneic NK cells are not genetically modified but are grown in culture to increase their numbers and enhance their cytotoxic activity. The primary mechanism of action is direct immunomodulation and cytotoxicity against tumor or abnormal target cells through recognition of stress ligands and absence of self-MHC on malignant or infected targets. Cord blood is used as the source due to its accessibility, lower risk of graft-versus-host disease, and ability to generate large numbers of functional NK cells after expansion. This therapy is being investigated primarily for hematologic malignancies (such as multiple myeloma) and solid tumors (including osteosarcoma, Ewing sarcoma, synovial sarcoma), especially in relapsed/refractory settings[2][3][4][6]. The product may be administered following lymphodepleting chemotherapy to facilitate engraftment and persistence.
- Other names
- cord blood-derived expanded NK cellsCB-NK cellsumbilical cord blood-derived natural killer cells
Beyond the preview
Go deeper on cord blood-derived expanded allogeneic natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cord blood-derived expanded allogeneic natural killer cells.